Document is current
Any future updates will be listed below
-
Authors
Pegoretti, Valentina https://orcid.org/0000-0003-1148-4541
Boerema, Ate https://orcid.org/0000-0002-4771-5156
Kats, Kim https://orcid.org/0000-0001-5300-2139
Dafauce Garcia, Juan M. https://orcid.org/0009-0004-8410-6407
Fischer, Roman https://orcid.org/0000-0001-7927-604X
Kontermann, Roland E. https://orcid.org/0000-0001-7139-1350
Pfizenmaier, Klaus https://orcid.org/0000-0002-3441-9227
Laman, Jon D. https://orcid.org/0000-0001-5085-9807
Eisel, Ulrich L. M. https://orcid.org/0000-0003-4178-0384
Baron, Wia https://orcid.org/0000-0002-6673-4766
-
Funding
Funding for this research was provided by:
Stichting MS Research (15-898 MS, 15-898 MS, 15-898 MS)
- License Information
-
More Information
Article History
Received: 28 October 2024
Revised: 6 April 2025
Accepted: 22 April 2025
First Online: 10 May 2025
Declarations
:
: Animal procedures were approved by the Central Authority for Scientific Procedures on Animals (CCD, AVD105002016504) and the Animal Care and Use Committee of the University of Groningen (IvD, 16504–04-02) and were carried out in conformity with Directive 2010/63/EU.
: R.F. and R.E.K. are named inventors on a patent covering the TNFR2 agonist. R.E.K. is a consultant for Immatics, Roche, SunRock, and Oncomatryx. K.P. is a consultant for BioNtech, SunRock, and Oncomatryx.
